British holidaymaker in critical condition after catching Legionnaires' disease in Crete
A British tourist is in intensive care after catching a serious lung disease while on holiday in Greece.
Donna Jobling from Hull was on an all-inclusive holiday on the Greek island of Crete when she fell ill on 6 June.
Her condition continued to worsen over the next two days and she was admitted to hospital in Heraklion.
The 57-year-old had caught Legionnaires' disease, a lung infection you can get after inhaling droplets of water from things like air conditioning or hot tubs.
A doctor told Ms Jobling's husband, Sid, that her lungs were quickly shutting down, then she was put into an induced coma.
She and her husband had been travelling with easyJet holidays. "We're so sorry to hear that Ms Jobling is unwell, and we're continuing to support her and her family in every way we can," a spokesperson for the holiday provider said.
While it is not confirmed that the hotel is the source of the infection, as a precaution customers were moved out and have been provided alternative hotel accommodation. Those planning to stay in the hotel over the next four weeks have also been given alternative options.
As well as moving other customers out of the hotel, easyJet Holidays said it has been in touch with customers who have recently returned home from the hotel.
"Our customers' safety and wellbeing is our top priority, and we'll continue to do all we can to support them,' the spokesperson said.
The hotel where Ms Jobling fell ill is currently working with local health authorities on the island.
'Donna has an abundance of loving family and friends who just want to get the chance to go over there to support her and Sid, who is currently there alone and has been for two weeks,' a GoFundMe fundraising page for Ms Jobling says.
The fundraiser, organised by Ms Jobling's niece, has raised £510 out of an £1,200 target as of Monday morning.
It added: 'We really don't know what the outcomes can be at this point, with very little good news from doctors. Anything will help at this hard time; we just need people there to support them.'
Ms Jobling has been in the intensive care unit in critical condition since 11 June.
The UK's Foreign, Commonwealth & Development Office said it is supporting the family and is in contact with the local authorities.
After Ms Jobling was hospitalised, the Greek health ministry issued a statement to hoteliers in Crete to "raise awareness among all those involved in monitoring the quality of water for human consumption especially with regard to Legionella".
The disease is uncommon, but it can be very serious. It is unclear what caused the infection, but you can usually contract the illness by inhaling tiny droplets of water containing bacteria.
The disease tends to be caught in places like hotels, as well as hospitals and offices, where bacteria have got into the water supply.
Symptoms include coughing, shortness of breath, chest pain or discomfort, a high temperature and flu-like symptoms.
An emergency alert has also been issued on the island by the European Centre for Disease Prevention and Control following the diagnosis.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
36 minutes ago
- Medscape
ASCO 2025: Impact of Therapeutic Advances in Prostate Cancer
Petros Grivas, MD, shares key updates from ASCO 2025, focusing on advances in prostate cancer across disease stages. He highlights promising results from the AMPLITUDE trial showing a radiographic progression-free survival benefit with niraparib plus abiraterone in patients with BRCA-mutated tumors and anticipated further data from the PSMAddition trial involving lutetium-PSMA. Additional discussions included prostate-specific antigen nadir as a prognostic marker, quality-of-life outcomes from the ARANOTE trial, and emerging therapies like BiTEs and theranostics for castration-resistant disease. He emphasizes the importance of somatic and germline testing in personalizing treatment and improving outcomes for both patients and their families.


WebMD
an hour ago
- WebMD
How to Finally Treat Acne Scars (Without Wasting Time or Money)
Acne may fade, but the scars it leaves behind can linger for years – both on the skin and emotionally. For many, acne scars affect self-esteem and confidence, long after the last breakout has healed. The good news: Today's acne scar treatments are more effective, personalized, and safer than ever. The key is knowing what type of scars you have and how to match them with the most appropriate therapy. Understanding Your Acne Scars Not all acne scars are the same. Each type responds differently to treatment, so accurate identification is an important first step. Ice pick scars: Deep, narrow scars that resemble small puncture marks. Often considered one of the most challenging types to treat. Think V-shaped. Boxcar scars: Broad, well-defined depressions with sharp edges, commonly seen on the cheeks and temples. Think U-shaped. Rolling scars: Shallow, wave-like indentations caused by bands of scar tissue pulling down the skin. Hypertrophic or keloid scars: Raised, thickened scars often found on the chest, shoulders, or jawline. Post-inflammatory hyperpigmentation (PIH) or erythema (PIE): Red or dark discoloration that remains after acne resolves, especially common in skin of color. While technically not a true scar, they can feel like it! Accurate diagnosis leads to more successful outcomes and avoids the trial and error that can waste both time and money. There Is No Universal 'Fix' Despite online claims, no single product or procedure treats every type of acne scar. Treatment needs to be customized based on scar type, skin tone, and individual goals. Be cautious of 'miracle' solutions or overly aggressive procedures that promise dramatic results overnight. Evidence-Based Treatments That Work Here are some of the most effective, dermatologist-approved methods: Subcision and Laser-Assisted Subcision Ideal for rolling scars, subcision involves releasing the fibrous bands beneath the skin that cause depressions. When combined with laser therapy, it also stimulates collagen for smoother skin. Microneedling With Radiofrequency This combines fine needles with thermal energy to remodel skin and improve texture. It is a preferred option for moderate scarring and has minimal downtime. TCA CROSS (Chemical Reconstruction of Skin Scars) This technique uses a high-strength acid like TCA or phenol, applied directly into ice pick scars to stimulate collagen production. It's highly targeted and effective for deep, narrow scars. Laser Resurfacing Ablative lasers like CO2 or erbium can improve skin texture and depth of scarring. Caution is advised for people with darker skin tones to reduce the risk of pigmentation issues. Topical Treatments for Pigmentation When scars leave behind discoloration, the following options can be effective: Broad-spectrum sunscreen used daily Tretinoin to increase skin turnover and collagen boosting Brightening agents such as vitamin C, niacinamide, azelaic acid, and tranexamic acid Lasers and chemical peels may also be used as a second step, once inflammation has resolved. Don't Overlook Fillers and Biostimulatory Treatments For certain types of depressed acne scars – like rolling or boxcar scars – injectables can offer fast and visible improvement. These are especially helpful when used alongside other treatments like subcision or microneedling. Here's how they work: Hyaluronic acid fillers: Add immediate volume to lift indented scars and smooth the skin's surface. Results are visible right away and can last six to 12 months. Biostimulatory injectables (like Sculptra or Radiesse): They do more than just fill. These stimulate your skin's natural collagen production for gradual, longer-lasting improvement, and they're especially useful in combination treatments. Combination therapy: This is often used after subcision to hold the skin up and prevent the scar from tethering down again. While not a permanent fix, fillers can be a powerful tool in your acne scar treatment plan, especially if you're looking for quicker wins while working on long-term skin texture. Address Active Acne First Scar treatments are only effective when active acne is controlled. Initiating scar therapy while breakouts continue can undermine results and increase the risk of complications. Begin by managing active acne to set the foundation for long-term skin health. Set Realistic Expectations While complete scar removal is unlikely, significant improvement – often 30% to 50% – is achievable. These changes can make a major difference in how the skin looks and feels, contributing to greater self-confidence and comfort. Navigating the world of acne scar treatments can be overwhelming. With an accurate diagnosis, evidence-based therapies, and a personalized approach, real and lasting improvement is possible. Rather than chasing quick fixes, focus on progress. The skin has an impressive ability to heal with the right support – and your path to smoother, more confident skin may be closer than you think.
Yahoo
an hour ago
- Yahoo
Biosimilars Market Outlook, Growth Trends, Regulatory Landscape and Opportunities 2025–2034
Luton, Bedfordshire, United Kingdom, June 23, 2025 (GLOBE NEWSWIRE) -- Biosimilars Market Report: 2024–2025 Overview Foreword Biosimilars have emerged as a powerful tool in the global healthcare arsenal, delivering cost-effective alternatives to high-priced biologics and expanding patient access. As policymakers, payers, providers, and manufacturers align incentives around value, biosimilars are reshaping therapeutic landscapes and fueling generics-style competition in biologics. Download PDF Brochure: The biosimilars market is anticipated to reach a valuation of approximately $25 billion in 2024, driven by increasing demand for cost-effective biologic therapies and a growing prevalence of chronic diseases. The market is projected to expand significantly, with an estimated value of $60 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of around 9% during the forecast period from 2025 to 2034. Segmentation By Product, Indication, and Region. BY PRODUCT Monoclonal Antibodies Infliximab Trastuzumab Rituximab Adalimumab Other Insulin Granulocyte Colony-Stimulating Factor Erythropoietin Recombinant Human Growth Hormone Etanercept Follitropin Teriparatide Interferons Enoxaparin Sodium Glucagon Calcitonin BY INDICATION Oncology Inflammatory & Autoimmune Disorders Chronic Diseases Blood Disorders Growth Hormone Deficiency Infectious Diseases Others BY REGION North America Europe Asia Pacific South America Middle East and Africa As one health policy expert remarked during a POLITICO Focus roundtable: > 'Experts explored the pivotal role that biosimilars play in strengthening the nation's health care system…' Scientific and regulatory leaders also emphasize mitigating biases and reinforcing confidence. Professor Schellekens notes: > 'Biosimilars often have even a higher quality than the reference products.' Additional insights from industry leaders underline the ongoing transformation: - Sarah Yim (FDA): 'Both biosimilars and interchangeable biosimilars meet the same high standard of biosimilarity for FDA approval and both are as safe and effective as the reference product.' - Adam Fein (Drug Channels): 'For 2025, the three largest pharmacy benefit managers… have again each excluded hundreds of drugs from their standard formularies… creating an increasingly confusing and crowded biosimilar marketplace.' - Alex Brill (Matrix Global Advisors): 'Is the biosimilar market a failure with respect to these pharmacy benefit drugs like Humira? Maybe in March it was, but in April it's starting to look functional again.' - Jon Martin (Organon): 'That's what gives us some optimism,' referring to expectations that biosimilars can gain ~50% share over time, as seen with Remicade. - AMCP 2025 Reports: 'High adherence rates, comparable clinical effectiveness, and cost savings have marked the early adoption of adalimumab biosimilars in the US.' - Sandoz Spokesperson: 'Misaligned incentives across the US healthcare system have led to meaningful delays and barriers to biosimilar adoption, resulting in significant missed opportunities for healthcare savings.' Browse full Report - Market Size & Segmentation Global Valuation & Growth: USD 18.65 billion (2024), rising to 21.95 billion in 2025. Estimated CAGR: 17.7% to USD 42.16 billion by 2029. Other projections suggest growth from USD 40.4 billion (2025) to USD 176 billion by 2034 at 17.8% CAGR. Segmentation: By Therapeutic Area: Oncology, autoimmune diseases, metabolic disorders. By Molecule Type: Monoclonal antibodies, G-CSF, insulin, epoetins. By Application: Chronic and acute care. By Region: North America, Europe, Asia-Pacific, Latin America, Middle East & Africa. Key Players Established Leaders: Amgen, Novartis/Sandoz, Samsung Bioepis, Pfizer, Celltrion, Biogen, Coherus, Merck & Co., Dr. Reddy's, Biocon, Intas. Emerging Names: CVS/Cordavis, Alvotech, Kashiv BioSciences, Fresenius Kabi. Key Market Events (2024–2025) FDA Approvals: Over 60 biosimilars approved in the U.S. as of late 2024. Ustekinumab Biosimilars Launch: Products like Wezlana, Pyzchiva, and Imuldosa began sales in Q1 2025. CVS Cordavis x Sandoz: Hyrimoz launched as a private-label biosimilar for Humira in the U.S. (Apr 2024). Humira Dynamics: Despite biosimilar competition, Humira retained over 80% U.S. market share in 2024 due to PBM rebates. India Rule Overhaul: Indian regulators revised biosimilar manufacturing and quality frameworks (May 2025). Recent Company Developments: Adalimumab Biosimilars (2024–2025) 1. Amgen – Amjevita Key 2025 Development: Listed as a preferred biosimilar on the Optum Rx formulary, which is one of the largest pharmacy benefit managers (PBMs) in the U.S. This significantly improves market access. Real-World Evidence (RWE): Amgen has emphasized clinical performance data and safety outcomes to support payer decisions. The strong RWE backing is helping Amjevita remain competitive despite the influx of newer biosimilars. Market Insight: Despite being the first biosimilar launched in the U.S. (January 2023), initial uptake was slow due to high WAC pricing. However, Amgen's subsequent pricing strategies and improved payer contracts have revitalized adoption. 2. Boehringer Ingelheim – Cyltezo Milestone Achievement: Cyltezo remains the only FDA-approved interchangeable biosimilar to Humira that is available in both high- and low-concentration formulations. Market Differentiation: Interchangeability status is a key competitive edge as it allows automatic substitution at the pharmacy level (subject to state laws), improving prescription volume. Strategic Positioning: Being early to achieve interchangeability has helped Boehringer establish trust among prescribers and pharmacists, especially in rheumatology and gastroenterology. 3. Sandoz – Hyrimoz Recent Development: Though initially launched with multiple dosage strengths (including citrate-free and high-concentration options), Hyrimoz faced formulary exclusion in 2025 from several key PBMs. Market Impact: This exclusion impacted Sandoz's market share, pushing the company to focus on institutional sales and non-PBM-aligned providers. Commercial Focus: Sandoz is working on reinforcing relationships with IDNs (Integrated Delivery Networks) and specialty clinics to maintain uptake. 4. Coherus BioSciences – Yusimry Remarkable Market Share: By early 2025, Yusimry had captured ~33% of the rheumatology market, becoming a major player. Cost Leadership Strategy: Coherus pursued an aggressive low-cost model, offering Yusimry at a 70–85% discount to branded Humira. Retail Success: Coherus partnered with Mark Cuban's Cost Plus Drug Company, making Yusimry directly accessible to consumers at discounted prices, thereby bypassing traditional PBMs. 5. Biocon Biologics / Viatris (Mylan) – Hulio Key Update: In June 2025, Hulio received FDA interchangeability designation, allowing it to be substituted for Humira at the pharmacy level. Competitive Edge: This places Hulio in a more favorable reimbursement tier, potentially improving market access in the latter half of 2025. Partnership Model: Now solely marketed by Biocon (after acquiring Viatris' biosimilar business), Hulio's commercialization is focused on cost competitiveness and institutional penetration. 6. Pfizer – Abrilada Launch Recap: Though approved earlier, Pfizer launched Abrilada in late 2023. By 2024–2025, it secured strong placement in major PBM formularies, including CVS Caremark. Advantages: Abrilada benefits from Pfizer's established distribution network and payer negotiation strength. Clinical Support: Pfizer's robust clinical trial data and real-world validation helped in promoting Abrilada among conservative prescribers. 7. Organon / Samsung Bioepis – Hadlima Dosing Options: Hadlima is unique in offering multiple administration options, including autoinjectors and prefilled syringes with both high- and low-concentration versions. Evolving Formulary Position: While not the first-mover, Hadlima is gradually gaining access across PBMs and health systems by undercutting competitors on pricing and offering flexibility in administration. Target Market: Focused on dermatology and GI segments due to its versatility and delivery mechanisms. 8. Celltrion – Yuflyma High-Concentration Formulation: One of the few biosimilars that mimic the high-concentration, citrate-free version of Humira, preferred by many patients due to reduced injection volume and discomfort. Interchangeability Status: Expected by late 2024, this could significantly enhance Yuflyma's market access through automatic substitution pathways. Commercial Strength: Celltrion's U.S. entry has been backed by a direct sales force and aggressive discounting. 9. Fresenius Kabi – Idacio Institutional Play: Idacio is marketed primarily in low-concentration injectable form, making it attractive for hospital and outpatient clinic use. Strategic Niche: Rather than competing head-on in retail, Fresenius is targeting group purchasing organizations (GPOs) and long-term care facilities. Moderate Uptake: While slower in market penetration, its institutional strategy is ensuring a steady adoption curve. 10. Alvotech – Simlandi Key Approval: In February 2024, Alvotech's Simlandi became the first high-concentration Humira biosimilar to gain FDA approval with interchangeability. Significance: This combination (high concentration + interchangeability) makes Simlandi a major competitive threat to both Amjevita and Yuflyma. Commercial Expansion: Alvotech is partnering with Teva for U.S. commercialization and focusing on payer contracts and formulary inclusion throughout 2025. Buy Now: Key Funding Deals (2024–2025) Biocon Biologics: Continued global expansion and investment. Bio-RIDE Scheme (India): $1.2B biotech initiative supporting biosimilar development. Cloudsek (APAC threat analytics): $19M funding round relevant to regulatory compliance and digital oversight. Government Initiatives & Regulations U.S. FDA Biosimilars Action Plan: Ongoing efforts to improve biosimilar approvals, labeling, and interchangeability. BPCI Act: Continues to guide abbreviated regulatory pathway for biosimilar market entry. Bio-RIDE Scheme (India): Supporting local biotech infrastructure and biosimilar manufacturing. EU and UK Regulatory Expansion: EU's centralized procedure and NHS guidance help drive biosimilar uptake. Most Sold Biosimilars by Region USA: - High-volume products: Filgrastim (Zarxio), Pegfilgrastim, Rituximab, Bevacizumab, Infliximab, Ranibizumab. - 2024 Adoption Trend: Humira biosimilars like Amjevita, Hyrimoz, Cyltezo, Simlandi began capturing 20%+ share. Europe: - Dominant biosimilars: Adalimumab (Amgevita, Hulio), Infliximab (Remsima, Inflectra), Etanercept (Benepali), Aflibercept, Ustekinumab. APAC: - Top products: Truxima, Remsima, Herzuma (Infliximab biosimilars); Yuflyma, Cadalimab (Adalimumab). - Usage Drivers: Broad use in India, China, South Korea; strong domestic production. LATAM: - Common imports: Remsima, Amgevita, Benepali. - Adoption via: Public tenders in Brazil, Mexico, and Argentina. Volume-Based Rankings & Sales Figures USA: - Filgrastim: ~88% volume share. - Pegfilgrastim: ~82% share. - Rituximab: ~76% share. - Bevacizumab: ~64% share. - Infliximab: ~49% share. - Ranibizumab: ~42–51% share. - Humira Biosimilars: USD 1.54B in 2025, forecast to USD 7.7B by 2032 (26% CAGR). EU: - IQVIA estimate: ~30–37% of total biologic volume from biosimilars. APAC: - Regional Revenue: USD 8.43B (2023), forecast to USD 46B by 2033. LATAM: - Limited data: Highest volume for infliximab, adalimumab via EU imports. The biosimilars market is rapidly advancing toward USD 90–176 billion by 2034, propelled by patent cliffs (e.g., Humira, Stelara), policy reforms, payer cost pressures, and improved trust in biosimilar interchangeability. As stakeholders navigate volume penetration, pricing battles, and rebate challenges, success will rely on clear clinical guidance, supply chain localization, and educational outreach. This report compiles key data for manufacturers, investors, regulators, and health systems to strategize entry, pricing, policy, and growth in biosimilars across therapeutic classes and global markets. Request Sample Pages: More Research Finding – Golimumab Simponi Market The global market for Golimumab (Simponi) is valued at approximately $3.5 billion, driven by increasing prevalence of autoimmune diseases such as rheumatoid arthritis, ulcerative colitis, and psoriasis. The market is projected to reach $5.2 billion by 2034, reflecting a robust demand for biologics in immunotherapy. Ranibizumab Market The global Ranibizumab market is projected to reach a value of approximately $10.5 billion in 2024, driven by increasing prevalence of retinal diseases such as age-related macular degeneration (AMD) and diabetic retinopathy. During the forecast period from 2025 to 2034, the market is expected to grow significantly, with a projected value of around $16.2 billion by 2034, translating to a Compound Annual Growth Rate (CAGR) of 4.5%. Aflibercept Biosimilars Market The global market for Aflibercept biosimilars is valued at approximately $1.2 billion, reflecting a surge in demand driven by increasing prevalence of retinal diseases and rising healthcare costs associated with novel therapies. The market is projected to reach around $4.6 billion by 2034, demonstrating robust expansion in a landscape characterized by an influx of biosimilar entrants and heightened competition within the pharmaceutical sector. Procarbazine Market The global procarbazine market is estimated to hold a value of approximately $120 million in 2024, driven by its critical application in treating various types of cancer, including Hodgkin's lymphoma. As awareness of cancer treatment advancements rises and with ongoing clinical trials exploring new applications, the market is projected to reach around $180 million by 2034. This growth reflects a Compound Annual Growth Rate (CAGR) of about 4.3% during the forecast period from 2025 to 2034. U.S. Generic Injectables Market The U.S. generic injectables market is estimated to reach a value of approximately $55 billion in 2024, buoyed by the increasing demand for cost-effective alternatives to brand-name drugs and a growing prevalence of chronic diseases. The market is projected to grow at a Compound Annual Growth Rate (CAGR) of around 7% from 2025 to 2034. Understanding Growth Hormone Deficiency Market The global growth hormone deficiency (GHD) market is valued at approximately $4.8 billion, driven by increasing prevalence rates, advances in recombinant human growth hormone therapies, and greater awareness of GHD among healthcare professionals. The market is expected to grow significantly, achieving a projected value of $7.2 billion by 2034, indicating a robust expansion trajectory. Insulin Biosimilars Market The global insulin biosimilars market is valued at approximately $5.8 billion in 2024, driven by an increasing prevalence of diabetes and the rising demand for cost-effective therapeutic options. The market is projected to grow to around $13.2 billion by 2034, representing a robust Compound Annual Growth Rate (CAGR) of 8.5% during the forecast period from 2025 to 2034. Human Insulin Market The human insulin market is expected to grow at 6.14 % CAGR from 2021 to 2029. It is expected to reach above USD 40.45 Billion by 2029 from USD 23.05 Billion in 2020. Bioprocess Technology Market The bioprocess technology market is expected to grow at 15.2% CAGR from 2022 to 2029. It is expected to reach above USD 61805.63 million by 2029 from USD17296.4 million in 2022. Autoimmune Monoclonal Antibodies Market The market for autoimmune monoclonal antibodies is currently valued at approximately $160 billion in 2024, driven by increasing prevalence of autoimmune diseases and advancements in biopharmaceutical technology. The demand for targeted therapies is expected to fuel a robust growth trajectory, with a projected market value of $290 billion by 2034. This growth reflects a Compound Annual Growth Rate (CAGR) of around 6.3% during the forecast period from 2025 to 2034. Recombinant Insulin Analogue Market The recombinant insulin analogue market is poised for significant growth, currently valued at approximately $24.5 billion in 2024. This market is projected to reach around $45 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period of 2025–2034. Lymphopenia Therapeutics Market The global lymphopenia therapeutics market is valued at approximately $3.2 billion, driven by increasing awareness of immune disorders and advancements in biologics and immunotherapies. The market is projected to grow significantly, reaching an estimated $6.8 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of around 8.1% during the forecast period of 2025 to 2034. Demyelinating Diseases Therapeutics Market The global market for demyelinating diseases therapeutics is valued at approximately $25 billion in 2024, with projections indicating substantial growth, reaching an estimated $45 billion by 2034. This reflects a robust Compound Annual Growth Rate (CAGR) of around 6.3% during the forecast period from 2025 to 2034. SOX2 Antibody Market The global SOX2 antibody market is valued at approximately $250 million in 2024 and is projected to reach around $450 million by 2034. This indicates a robust growth trajectory, with a compound annual growth rate (CAGR) of about 6.5% during the forecast period from 2025 to 2034. VDAC1 Antibody Market The VDAC1 antibody market is poised for significant growth, anticipated to reach a value of approximately $220 million in 2024. Projections suggest that the market could expand to around $480 million by 2034, reflecting the increasing prevalence of chronic diseases and the rising demand for targeted therapies. This trajectory indicates a Compound Annual Growth Rate (CAGR) of about 8.1% during the period from 2025 to 2034. Anti-Olig2 Antibody Market The global market for Anti-Olig2 antibodies is estimated to reach approximately $150 million in 2024, driven by increasing research activities in neurodegenerative diseases and developments in cancer immunotherapy. During the forecast period from 2025 to 2034, the market is projected to grow at a compound annual growth rate (CAGR) of 6.5%, potentially reaching around $325 million by 2034. CONTACT: Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@